Inventor · disambiguated record
Michel Janicot
Also filed as: JANICOT MICHEL · JANICOT MICHEL MARIE FRANCOIS
8 granted patents·11 pending applications·2 citations·filing 2003–2021
75Inventor score
Files withISARNA THERAPEUTICS GMBH8INTERNA TECH B V3JANSSEN PHARMACEUTICA NV3ARTS JANINE2FREYNE EDDY JEAN EDGARD2
Top patents by PatentIndex Score
19 records- 0169US9688988B2Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2014·Granted Jun 27, 2017·1 cites·11 claims
- 0262US7214705B2Bafilomycin-like metabolite from a novel micromonospora speciesJANSSEN PHARMACEUTICA NV·Filed 2003·Granted May 8, 2007·1 cites·4 claims
- 0357US2008213275A1Use of mtki 1 for treating or preventing bone cancerFREYNE EDDY JEAN EDGARD·Filed 2007·Application pending·0 cites
- 0456US7803600B2Micromonospora species that produces a bafilomycin-like metaboliteJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Sep 28, 2010·0 cites·2 claims
- 0555US9926563B2Modified TGF-beta oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2014·Granted Mar 27, 2018·0 cites·10 claims
- 0654US9840707B2Modified TGF-beta2 oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2014·Granted Dec 12, 2017·0 cites·6 claims
- 0754US2019144865A1Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2018·Application pending·0 cites
- 0852US10125368B2Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic diseaseISARNA THERAPEUTICS GMBH·Filed 2017·Granted Nov 13, 2018·0 cites·9 claims
- 0949US10538768B2Modified TGF-beta oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2018·Granted Jan 21, 2020·0 cites·5 claims
- 1048US2022098595A1Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their useNAYAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1147US2023136088A1miRNA-193a for Promoting Immunogenic Cell DeathINTERNA TECH B V·Filed 2021·Application pending·0 cites
- 1246US2018087055A1Modified tgf-beta2 oligonucleotidesISARNA THERAPEUTICS GMBH·Filed 2017·Application pending·0 cites
- 1346US2008153853A1Use of mtki 1 for treating or preventing brain cancerFREYNE EDDY JEAN EDGARD·Filed 2007·Application pending·0 cites
- 1444US2022275368A1New treatments involving mirna-193aINTERNA TECH B V·Filed 2020·Application pending·0 cites
- 1542US2010298403A1MODIFIED POLY(PROPYLENE-IMINE) DENDRIMERS AND THEIR USE AS TRANSFECTION AGENTS FOR AMIONIC BIOACTIVE FACTORS ( as amendedJANSSEN PHARMACEUTICA NV·Filed 2006·Application pending·0 cites
- 1639US2009270419A1Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitorsARTS JANINE·Filed 2007·Application pending·0 cites
- 1739US2009312284A1Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitorsARTS JANINE·Filed 2007·Application pending·0 cites
- 1837US11207341B2TGF-beta oligonucleotide for use in treatment of ophthalmic diseasesISARNA THERAPEUTICS GMBH·Filed 2017·Granted Dec 28, 2021·0 cites·18 claims
- 1937US2021038732A1Anticancer microrna and lipid formulations thereofINTERNA TECH B V·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michel Janicot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →